Clinical trial · Interventional
EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
A Phase I, Open-label, Dose-escalation, Safety Study of the Combination of EPO906 and Radiation Therapy for the Treatment of Patients With Cancer
NCT00328458CI-TRIAL-00089232completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Central Nervous System Neoplasms | Central Nervous System Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Head and Neck Neoplasms | Head and Neck Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EPO906 (epothilone B) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Cohort 1 Brain Tumors
- description
- The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
- interventionNames
- Drug: EPO906 (epothilone B)
- type
- EXPERIMENTAL
- label
- Cohort 2 Head and Neck Tumors
- description
- The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
- interventionNames
- Drug: EPO906 (epothilone B)
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Requires a minimum of 3 weeks of radiation therapy * Solid tumors with advanced or recurrent disease for which there is no standard therapy or tumors have failed standard therapy * World Health Organization (WHO) performance status equal to or less than 2 * Life expectancy equal to or greater than 3 months Exclusion Criteria: * Any peripheral neuropathy * Unresolved diarrhea greater than grade 1 * Patients who received any other investigational compound within the past 28 days * Severe cardiac insufficiency * Patients on Coumadin
References
Publications (0)
Data not yet available
No reference posted for this study.